The risk of aripiprazole orally disintegrating tablets combined with other drugs has not been systematically evaluated. In view of the effect of this product on the central nervous system, it should be used with caution when combined with other drugs and alcohol that act on the central nervous system. When carbamazepine is added to the treatment of aripiprazole, the dose of aripiprazole should be doubled. The increased dose should be based on clinical evaluation. When carbamazepine is stopped in combination therapy, the dose of aripiprazole should be reduced. Aripiprazole and drugs metabolized by cytochrome P450 are unlikely to produce clinically significant pharmacokinetic interactions.